UBE2A

Across TCGA pan-cancer cohorts, UBE2A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UBE2A data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher UBE2A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated UBE2A expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and GBM are the cancer types where UBE2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.799	0.434	.007	19	view →
PDAC	OS	Quartile	III,IV	0.938	0.383	.006	7	view →
GBM	DFS	Median	All	0.295	0.446	.041	2	view →
LSCC	OS	Tertile	All	0.856	0.963	.015	2	view →
HNSC	DFS	Median	All	0.723	0.830	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

UBE2A–LUAD (OS)

Open the LUAD breakdown →